Clinical trials: Malignant Melanoma Stage III
Stage IV Melanoma, Stage III Melanoma
TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma
This phase 2 trial will investigate the efficacy and safety of trametinib and dabrafenib in patients with advanced BRAF V600 (v-Raf murine sarcoma viral oncogene homolog B) wild-type melanoma (stratified according to BRAF V600…
- Trial name
- TraMel-WT (NCT04059224)
- Testing
- Trametinib, Dabrafenib
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- Universitair Ziekenhuis Brussel
Gastrinoma, Glucagonoma
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00655655
- Testing
- everolimus, vatalanib, pharmacological study
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Melanoma (Skin)
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00118274
- Testing
- incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine
- Where
- 3 sites in United States
- Volunteers
- 170 people
- Sponsor
- Craig L Slingluff, Jr
Melanoma, Melanoma Stage III
CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma
Combination treatment with nivolumab and ipilimumab before surgery may help people with melanoma because the drugs are designed to help the immune system target and destroy cancer cells (immunotherapy), which may shrink the…
- Trial name
- NCT05289193
- Testing
- PET Scan, Nivolumab, Ipilimumab
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Melanoma
Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
The primary goal of this study is to determine if people with metastatic melanoma who receive Heat Shock Protein-Peptide Complex - 96 (HSPPC-96 or Oncophage) after surgery live longer than people who may or may not have surgery…
- Trial name
- NCT00039000
- Testing
- HSPPC-96 or Oncophage
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 350 people
- Sponsor
- Agenus Inc.
Melanoma Stage III, Melanoma Stage IV
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for…
- Trial name
- INTACT/MeRCI (NCT06284590)
- Testing
- L19IL2, L19TNF, L19IL2/L19TNF
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 162 people
- Sponsor
- Philogen S.p.A.
Adjuvant, Stage III Malignant Melanoma
Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon
The study protocol is being conducted to compare intermittent high-dose i.v. administation of interferon alpha-2b with the standard high-dose treatment by Kirkwood with distant metastasis free survival (DMFI) as a primary…
- Conditions
- Adjuvant, Stage III Malignant Melanoma, Interferon Alpha, Therapy
- Trial name
- NCT00226408
- Testing
- Interferon-alpha-2b
- Where
- 13 sites in Germany
- Volunteers
- 600 people
- Sponsor
- Dermatologic Cooperative Oncology Group
Melanoma (Skin)
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Biological therapies such as interferon gamma and interleukin-2 use different ways to stimulate the immune system and…
- Trial name
- NCT00006113
- Testing
- MART-1 antigen, aldesleukin, gp100 antigen
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Southern California
Melanoma, Skin Cancer
Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00002882
- Testing
- Aldesleukin (IL-2), Recombinant Interferon Alfa (IFN-A), Cisplatin
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- M.D. Anderson Cancer Center
Stage IIIB Melanoma, Stage IIIC Melanoma
Dinaciclib in Treating Patients With Stage III-IV Melanoma
This is a phase I/II trial is studying the side effects and best dose of dinaciclib and to see how well it works in treating patients with advanced melanoma.
- Conditions
- Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Trial name
- NCT01026324
- Testing
- dinaciclib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Melanoma
Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut
It is a single-center, single-arm Phase II clinical study. This clinical trial aimed to evaluate the PFS of imatinib combined with toripalimab in stage III unresectable and stage IV melanoma with CKIT gene mutation.
- Trial name
- NCT05274438
- Testing
- JS001+Imatinib mesylate
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Peking University Cancer Hospital & Institute
Melanoma
Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma
The purpose of this research study is to learn about the safety and effectiveness of the study drug, PF-06688992. Before this study, PF-06688992 has never been given to people.
- Trial name
- NCT03159117
- Testing
- PF-06688992
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
This study is being conducted to compare the relationship of patient response to treatment to changes in tumor environment.
- Trial name
- NCT03002376
- Testing
- REGN2810
- Where
- 8 sites in Netherlands, Serbia and 2 more
- Volunteers
- 47 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable).
- Conditions
- Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary
- Trial name
- NCT04462406
- Testing
- Ipilimumab, Nivolumab, Patient Observation
- Where
- 482 sites in United States
- Volunteers
- 150 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)
Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
The purpose of the study is to evaluate the pharmacokinetic (PK) equivalence of Bmab1800 as compared with reference product Keytruda® in a randomized, double-blind, two-arm, parallel comparative, multi-center study in patients…
- Trial name
- NCT07581509
- Testing
- Bmab1800, US-Licensed Keytruda
- Where
- Brazil
- Volunteers
- 138 people
- Sponsor
- Biocon Biologics UK PLC
Melanoma Stage Iv, Unresectable Stage III Melanoma
Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy
Altering the Gut Microbiota of Melanoma Patients Who Failed Immunotherapy Using Fecal Microbiota Transplantation (FMT) From Responding Patients. FMT includes both colonoscopy and stool capsules.
- Trial name
- NCT03353402
- Testing
- Fecal Microbiota Transplant (FMT)
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Sheba Medical Center
Melanoma Stage III, Melanoma Stage IV
A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma
There are in total 3 cohorts. Cohort A: 16 patients will receive a daily dose of 80mg regorafenib up until progressive disease, unacceptable toxicity or withdrawal of consent.
- Trial name
- RegoMel (NCT05370807)
- Testing
- Regorafenib 40 MG Oral Tablet, Triplet therapy
- Where
- Belgium
- Volunteers
- 48 people
- Sponsor
- Universitair Ziekenhuis Brussel
Recurrent Melanoma, Stage IIIB Skin Melanoma
Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with stage III-IV melanoma that has spread to other places in the body and usually cannot be cured or controlled with treatment…
- Conditions
- Recurrent Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
- Trial name
- NCT01744171
- Testing
- Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Roswell Park Cancer Institute
Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
This phase Ib/II trial studies the side effects and best dose of plinabulin in combination with radiation therapy and immunotherapy in patients with select cancers that have spread to other places in the body (advanced) after…
- Conditions
- Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT04902040
- Testing
- Atezolizumab, Avelumab, Durvalumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma (Skin), Sarcoma
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Infusing chemotherapy to the tumor area only may kill more tumor cells and cause less damage to healthy…
- Trial name
- NCT00004250
- Testing
- dactinomycin, isolated limb perfusion, melphalan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center